Clinicopathological characteristics and prognosis of stage IV colorectal cancer

Miyoshi,Norikatsu; Ohue,Masayuki; Shingai,Tatsushi; Noura,Shingo; Sugimura,Keijiro; Akita,Hirofumi; Gotoh,Kunihito; Motoori,Masaaki; Takahashi,Hidenori; Kishi,Kentaro; Okami,Jiro; Marubashi,Shigeru; Fujiwara,Yoshiyuki; Higashiyama,Masahiko; Yano,Masahiko

doi:10.3892/mco.2015.598

September-2015 Volume 3 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

September-2015 Volume 3 Issue 5

Full Size Image

Article

Clinicopathological characteristics and prognosis of stage IV colorectal cancer

Authors:
- Norikatsu Miyoshi
- Masayuki Ohue
- Tatsushi Shingai
- Shingo Noura
- Keijiro Sugimura
- Hirofumi Akita
- Kunihito Gotoh
- Masaaki Motoori
- Hidenori Takahashi
- Kentaro Kishi
- Jiro Okami
- Shigeru Marubashi
- Yoshiyuki Fujiwara
- Masahiko Higashiyama
- Masahiko Yano
View Affiliations / Copyright

Affiliations: Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Osaka 537‑8511, Japan, Department of Surgery, Saiseikai Senri Hospital, Suita, Osaka 565-0862, Japan
Pages: 1093-1098
|
Published online on: July 8, 2015

https://doi.org/10.3892/mco.2015.598
Expand metrics +

Abstract

The aim of this study was to determine the role of curative resection in metastatic colorectal cancer (CRC) and determine the subset of patients who may benefit from concurrent curative resection of primary and metastatic lesions. A total of 103 patients diagnosed with synchronous liver and/or lung metastatic CRC at the Osaka Medical Center for Cancer and Cardiovascular Diseases between 1983 and 2010 were retrospectively investigated. All the patients underwent curative resection of the primary and metastatic lesions. The median follow‑up time was 5.69 years. a total of 83 and 13 patients had only liver or lung metastasis, respectively, whereas 7 patients had synchronous liver and lung metastases. A total of 25 patients (24.2%) had no recurrence following curative resection and 14 patients (13.5%) received more than one re‑resection for disease recurrence and survived without any further recurrence thereafter. The 5‑year survival of liver or lung metastatic CRC was 43.7 or 90.0%, respectively. However, the median overall survival (OS) in patients with synchronous liver and lung metastases was 20.7 months. In the univariate and multivariate analyses, tumour invasion, synchronous liver and lung metastases and time‑to‑recurrence after the first curative resection were significantly associated with OS and disease‑free survival. In conclusion, curative resection confers longer‑term survival in patients with liver or lung metastatic CRC.

View Figures

View References

1	Jemal A, Siegel R, Xu J, et al: Cancer statistics 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
2	Headrick JR, Miller DL, Nagorney DM, et al: Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann Thorac Surg. 71:975–979; discussion 979–980. 2001. View Article : Google Scholar : PubMed/NCBI
3	Park JH, Kim TY, Lee KH, et al: The beneficial effect of palliative resection in metastatic colorectal cancer. Br J Cancer. 108:1425–1431. 2013. View Article : Google Scholar : PubMed/NCBI
4	Kanzaki R, Higashiyama M, Oda K, et al: Outcome of surgical resection for recurrent pulmonary metastasis from colorectal carcinoma. Am J Surg. 202:419–426. 2011. View Article : Google Scholar : PubMed/NCBI
5	Grothey A, Sargent D, Goldberg RM, et al: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan and oxaliplatin in the course of treatment. J Clin Oncol. 22:1209–1214. 2004. View Article : Google Scholar : PubMed/NCBI
6	Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
7	Sobrero AF, Maurel J, Fehrenbacher L, et al: EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 26:2311–2319. 2008. View Article : Google Scholar : PubMed/NCBI
8	Watanabe T, Itabashi M, Shimada Y, et al: Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol. 17:1–29. 2012. View Article : Google Scholar : PubMed/NCBI
9	Sobin LH and Fleming ID: TNM Classification of Malignant Tumors7th. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Wiley-Blackwell; Oxford, UK: pp. 100–109. 2009
10	Bathe OF, Dowden S, Sutherland F, et al: Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma. BMC Cancer. 4:322004. View Article : Google Scholar : PubMed/NCBI
11	Kornmann M, Formentini A, Ette C, et al: Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment. Eur J Surg Oncol. 34:1316–1321. 2008. View Article : Google Scholar : PubMed/NCBI
12	Lan YT, Chang SC, Yang SH, et al: Comparison of clinicopathological characteristics and prognosis between early and late recurrence after curative surgery for colorectal cancer. Am J Surg. 207:922–930. 2014. View Article : Google Scholar : PubMed/NCBI
13	Derkinderen DJ, Boxma OJ, Koten JW, et al: Stochastic theory of oncogenesis. Anticancer Res. 10:497–504. 1990.PubMed/NCBI
14	Miyoshi N, Ishii H, Mimori K, et al: Abnormal expression of TRIB3 in colorectal cancer: a novel marker for prognosis. Br J Cancer. 101:1664–1670. 2009. View Article : Google Scholar : PubMed/NCBI
15	Koshariya M, Jagad RB, Kawamoto J, et al: An update and our experience with metastatic liver disease. Hepatogastroenterology. 54:2232–2339. 2007.PubMed/NCBI
16	Schwartzberg LS, Rivera F, Karthaus M, et al: PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 32:2240–2247. 2014. View Article : Google Scholar : PubMed/NCBI
17	Price TJ, Peeters M, Kim TW, et al: Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 15:569–579. 2014. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Clinicopathological characteristics and prognosis of stage IV colorectal cancer

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles